Amit Bar-Or, MD, FRCPC, FAAN, FANA

Experts discuss the challenges of detecting progression in multiple sclerosis (MS), addressing the lack of available assessment tools but the importance of patient-reported signs and symptoms.

Experts begin this series on smouldering multiple sclerosis (MS) highlighting our current understanding of pathophysiology, it’s prevalence, and how we may better detect it in the future.

Neurology experts discuss the mechanism of action of BTKi’s for the treatment of multiple sclerosis.

Experts lead a discussion about potential safety concerns of BTKi’s when treating patients with multiple sclerosis.

Patrick Vermersch, MD, PhD, and Krzysztof Selmaj, MD, PhD, provide an overview of the BTKi that are currently under investigation for MS, and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, discusses what in vivo and in vitro preclinical work in models of MS have shown.

Amit Bar-Or, MD, FRCPC, provides an overview of the history of BTKi’s as well as what makes this class of drug a promising target for relapsing and remitting forms of MS.

The chief of the Multiple Sclerosis Division, Perelman School of Medicine at the University of Pennsylvania emphasized current recommendations, which suggest patients with MS get vaccinated for COVID-19. [WATCH TIME: 3 minutes]

The chief of the Multiple Sclerosis Division at the Perelman School of Medicine, University of Pennsylvania, discussed recommendations for COVID-19 vaccination in this patient population, specifically for those on disease-modifying therapies. [WATCH TIME: 2 minutes]